Lu, S., Shih, J., Jang, T., Liam, C., & Yu, Y. (2021). Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence. Adv Ther.

Lu, Shun, Jin-Yuan Shih, Tae-Won Jang, Chong-Kin Liam, and Yongfeng Yu. "Afatinib As First-Line Treatment in Asian Patients With EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence." Adv Ther 2021.

Lu, Shun, et al. "Afatinib As First-Line Treatment in Asian Patients With EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence." Adv Ther 2021.